|
Vaccine Detail
Algenpantucel-L |
Vaccine Information |
- Vaccine Name: Algenpantucel-L
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007216
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CEACAM5 (CEA)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- MSLN
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant:
- Preparation: Algenpantucel-L is a whole-cell vaccine with a combination of 2 irradiated allogeneic PC cells lines (HAPa-1, HAPa-2) genetically engineered by retrovirus transduction to express the murine enzyme α(1,3)-galactosyltransferase (αGT) (McCormick et al., 2016).
- Description: A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells. (NCIT_C61082).
Phase II clinical trial data has been encouraging, particularly for patients who demonstrated humoral immunologic responses for pancreatic adenocarcinoma patients.(Coveler et al., 2016)
|
Host Response |
|
References |
Coveler et al., 2016: Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Immunotherapy. 2016; 8(2); 117-125. [PubMed: 26787078].
McCormick et al., 2016: McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Human vaccines & immunotherapeutics. 2016; 12(3); 563-575. [PubMed: 26619245].
NCIT_C61082: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61082]
|
|